Investor Overview Announcements Date Title 2021/02/17 OBI filed the application of Phase III human clinical study for the active cancer immunotherapy OBI-822, Adagloxad Simolenin, to the drug administrations in Argentina, Brazil, and South Africa 2020/01/26 Mr. Michael Chang and five other executives received an acquittal for insider trading case at second instance by Taiwan High Court Read More Annual Report 2019Annual Report (PDF) 2018Annual Report (PDF) See More Financial Report 2020Financial Report Q1 2019Financial Report Q1 See More Stock Quote See More Event Calendar See More Monthly Revenues See More Corporate GovernanceRead More StakeholderRead More Company Profile Read More
